Osteoarthritis Pain (Central Nervous System) - Drugs In Development, 2021

July 2021 | 291 pages | ID: O0272F569A89EN
Global Markets Direct

Abstracts

Osteoarthritis Pain (Central Nervous System) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain - Drugs In Development, 2021, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint injury, obesity and heredity. Treatment includes weight control, exercise and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 5, 24, 15, 1, 12, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Osteoarthritis Pain - Overview
Osteoarthritis Pain - Therapeutics Development
Osteoarthritis Pain - Therapeutics Assessment
Osteoarthritis Pain - Companies Involved in Therapeutics Development
Osteoarthritis Pain - Drug Profiles
Osteoarthritis Pain - Dormant Projects
Osteoarthritis Pain - Discontinued Products
Osteoarthritis Pain - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Osteoarthritis Pain, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Companies, 2021 (Contd..3)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Osteoarthritis Pain - Pipeline by Acadia Pharmaceuticals Inc, 2021
Osteoarthritis Pain - Pipeline by Achelios Therapeutics Inc, 2021
Osteoarthritis Pain - Pipeline by AlzeCure Pharma AB, 2021
Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals Inc, 2021
Osteoarthritis Pain - Pipeline by Andros Pharmaceuticals Co Ltd, 2021
Osteoarthritis Pain - Pipeline by AntalGenics SL, 2021
Osteoarthritis Pain - Pipeline by Antibe Therapeutics Inc, 2021
Osteoarthritis Pain - Pipeline by Apimeds Inc, 2021
Osteoarthritis Pain - Pipeline by APT Therapeutics Inc, 2021
Osteoarthritis Pain - Pipeline by Aquilus Pharmaceuticals Inc, 2021
Osteoarthritis Pain - Pipeline by AstraZeneca Plc, 2021
Osteoarthritis Pain - Pipeline by Axsome Therapeutics Inc, 2021
Osteoarthritis Pain - Pipeline by BriOri BioTech LLC, 2021
Osteoarthritis Pain - Pipeline by Calchan Ltd, 2021
Osteoarthritis Pain - Pipeline by Cara Therapeutics Inc, 2021
Osteoarthritis Pain - Pipeline by Centrexion Therapeutics Corp, 2021
Osteoarthritis Pain - Pipeline by Chromocell Corp, 2021
Osteoarthritis Pain - Pipeline by Concentric Analgesics Inc, 2021
Osteoarthritis Pain - Pipeline by Eccogene (Shanghai) Co Ltd, 2021
Osteoarthritis Pain - Pipeline by Eli Lilly and Co, 2021
Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals Inc, 2021
Osteoarthritis Pain - Pipeline by Ensign Pharmaceutical Inc, 2021
Osteoarthritis Pain - Pipeline by Eupraxia Pharmaceuticals Inc, 2021
Osteoarthritis Pain - Pipeline by EyePoint Pharmaceuticals Inc, 2021
Osteoarthritis Pain - Pipeline by Flexion Therapeutics Inc, 2021
Osteoarthritis Pain - Pipeline by Futura Medical Plc, 2021
Osteoarthritis Pain - Pipeline by GlaxoSmithKline Plc, 2021
Osteoarthritis Pain - Pipeline by Grunenthal GmbH, 2021
Osteoarthritis Pain - Pipeline by iN Therapeutics, 2021
Osteoarthritis Pain - Pipeline by Levicept Ltd, 2021
Osteoarthritis Pain - Pipeline by Novartis AG, 2021
Osteoarthritis Pain - Pipeline by Nuvo Pharmaceuticals Inc, 2021
Osteoarthritis Pain - Pipeline by Olatec Therapeutics LLC, 2021
Osteoarthritis Pain - Pipeline by OliPass Corporation, 2021
Osteoarthritis Pain - Pipeline by Ono Pharmaceutical Co Ltd, 2021
Osteoarthritis Pain - Pipeline by Paradigm Biopharmaceuticals Ltd, 2021
Osteoarthritis Pain - Pipeline by Peptide Logic LLC, 2021
Osteoarthritis Pain - Pipeline by Pfizer Inc, 2021
Osteoarthritis Pain - Pipeline by Pharmnovo AB, 2021
Osteoarthritis Pain - Pipeline by Propella Therapeutics Inc, 2021
Osteoarthritis Pain - Pipeline by ProteoThera Inc, 2021
Osteoarthritis Pain - Pipeline by RaQualia Pharma Inc, 2021
Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Osteoarthritis Pain - Pipeline by Rottapharm Biotech Srl, 2021
Osteoarthritis Pain - Pipeline by Sansho Co Ltd, 2021
Osteoarthritis Pain - Pipeline by Shionogi & Co Ltd, 2021
Osteoarthritis Pain - Pipeline by Shulov Innovative Science Ltd, 2021
Osteoarthritis Pain - Pipeline by Sorrento Therapeutics Inc, 2021
Osteoarthritis Pain - Pipeline by Symic Bio Inc, 2021
Osteoarthritis Pain - Pipeline by Taiwan Liposome Co Ltd, 2021
Osteoarthritis Pain - Pipeline by Techfields Pharma Co Ltd, 2021
Osteoarthritis Pain - Pipeline by Tissuetech Inc, 2021
Osteoarthritis Pain - Pipeline by Tris Pharma Inc, 2021
Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Inc, 2021
Osteoarthritis Pain - Pipeline by Virpax Pharmaceuticals Inc, 2021
Osteoarthritis Pain - Pipeline by Xalud Therapeutics Inc, 2021
Osteoarthritis Pain - Pipeline by Xgene Pharmaceutical Inc, 2021
Osteoarthritis Pain - Pipeline by Yooyoung Pharm Co Ltd, 2021
Osteoarthritis Pain - Pipeline by Zhejiang Yatai Pharmaceutical Co Ltd, 2021
Osteoarthritis Pain - Pipeline by ZYUS Life Sciences Inc, 2021
Osteoarthritis Pain - Dormant Projects, 2021
Osteoarthritis Pain - Dormant Projects, 2021 (Contd..1)
Osteoarthritis Pain - Dormant Projects, 2021 (Contd..2)
Osteoarthritis Pain - Dormant Projects, 2021 (Contd..3)
Osteoarthritis Pain - Dormant Projects, 2021 (Contd..4)
Osteoarthritis Pain - Discontinued Products, 2021
Osteoarthritis Pain - Discontinued Products, 2021 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development for Osteoarthritis Pain, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021